A prospective study including 444 elderly AML patients confirmed the prognostic significance of CD34+/CD38−/CD123+ at diagnosis for the clinical outcome of patients receiving intensive chemotherapy, but not for those treated with hypomethylating agents only [43]. The gene discussed is CD34; the disease is acute myeloid leukemia.